As suggested in the report of Toita et al. (2016), the efficient delivery of therapeutic anti-inflammatory molecules, interleukin (IL)-10, to macrophages can dramatically improve the therapeutic efficacy of obesity treatments [18]. Here, IL10 is linked to obesity due to melanocortin 4 receptor deficiency.